Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Glycaemic variability and its association with enteral and parenteral nutrition in critically ill ventilated patients.

Doola R, Greer RM, Hurford R, Flatley C, Forbes JM, Todd AS, Joyce CJ, Sturgess DJ.

Clin Nutr. 2018 Aug 16. pii: S0261-5614(18)31343-8. doi: 10.1016/j.clnu.2018.08.001. [Epub ahead of print]

PMID:
30170779
2.

On the Specification of Upward-Propagating Tides for ICON Science Investigations.

Forbes JM, Zhang X, Hagan ME, England SL, Liu G, Gasperini F.

Space Sci Rev. 2017 Oct;212(1-2):697-713. doi: 10.1007/s11214-017-0401-5. Epub 2017 Aug 3.

3.

Diabetes-Specific Formulae Versus Standard Formulae as Enteral Nutrition to Treat Hyperglycemia in Critically Ill Patients: Protocol for a Randomized Controlled Feasibility Trial.

Doola R, Todd AS, Forbes JM, Deane AM, Presneill JJ, Sturgess DJ.

JMIR Res Protoc. 2018 Apr 9;7(4):e90. doi: 10.2196/resprot.9374.

4.

Mitochondrial Dysfunction and Signaling in Diabetic Kidney Disease: Oxidative Stress and Beyond.

Flemming NB, Gallo LA, Forbes JM.

Semin Nephrol. 2018 Mar;38(2):101-110. doi: 10.1016/j.semnephrol.2018.01.001. Review.

PMID:
29602393
5.

Mitochondrial dysfunction in diabetic kidney disease.

Forbes JM, Thorburn DR.

Nat Rev Nephrol. 2018 May;14(5):291-312. doi: 10.1038/nrneph.2018.9. Epub 2018 Feb 19. Review.

PMID:
29456246
6.

Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction.

Borg DJ, Yap FYT, Keshvari S, Simmons DG, Gallo LA, Fotheringham AK, Zhuang A, Slattery RM, Hasnain SZ, Coughlan MT, Kantharidis P, Forbes JM.

Islets. 2018 Jan 2;10(1):10-24. doi: 10.1080/19382014.2017.1405189. Epub 2017 Dec 22.

7.

Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes.

Ward MS, Flemming NB, Gallo LA, Fotheringham AK, McCarthy DA, Zhuang A, Tang PH, Borg DJ, Shaw H, Harvie B, Briskey DR, Roberts LA, Plan MR, Murphy MP, Hodson MP, Forbes JM.

Sci Rep. 2017 Nov 9;7(1):15190. doi: 10.1038/s41598-017-15589-x.

8.

Increased liver AGEs induce hepatic injury mediated through an OST48 pathway.

Zhuang A, Yap FY, Bruce C, Leung C, Plan MR, Sullivan MA, Herath C, McCarthy D, Sourris KC, Kantharidis P, Coughlan MT, Febbraio MA, Hodson MP, Watt MJ, Angus P, Schulz BL, Forbes JM.

Sci Rep. 2017 Sep 25;7(1):12292. doi: 10.1038/s41598-017-12548-4.

9.

Vascular complications in diabetes: old messages, new thoughts.

Forbes JM, Fotheringham AK.

Diabetologia. 2017 Nov;60(11):2129-2138. doi: 10.1007/s00125-017-4360-x. Epub 2017 Jul 19. Review.

PMID:
28725914
10.

Effect of dietary advanced glycation end products on inflammation and cardiovascular risks in healthy overweight adults: a randomised crossover trial.

Baye E, de Courten MP, Walker K, Ranasinha S, Earnest A, Forbes JM, de Courten B.

Sci Rep. 2017 Jun 23;7(1):4123. doi: 10.1038/s41598-017-04214-6.

11.

A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabetes.

Salonen KM, Ryhänen SJ, Forbes JM, Härkönen T, Ilonen J, Simell O, Veijola R, Groop PH, Knip M.

Diabetes Metab Res Rev. 2017 May;33(4). doi: 10.1002/dmrr.2872. Epub 2017 Jan 23.

PMID:
27883367
12.

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.

Leung C, Herath CB, Jia Z, Andrikopoulos S, Brown BE, Davies MJ, Rivera LR, Furness JB, Forbes JM, Angus PW.

World J Gastroenterol. 2016 Sep 21;22(35):8026-40. doi: 10.3748/wjg.v22.i35.8026.

13.

Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.

Leung SS, Forbes JM, Borg DJ.

Curr Diab Rep. 2016 Oct;16(10):100. doi: 10.1007/s11892-016-0782-y. Review.

PMID:
27612847
14.

Targeting advanced glycation with pharmaceutical agents: where are we now?

Borg DJ, Forbes JM.

Glycoconj J. 2016 Aug;33(4):653-70. doi: 10.1007/s10719-016-9691-1. Epub 2016 Jul 9. Review.

PMID:
27392438
15.

Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.

Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, Koepsell H, Vallon V, Pollock C, Panchapakesan U, Forbes JM.

Sci Rep. 2016 Jul 7;6:28124. doi: 10.1038/srep28124. No abstract available.

16.

Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?

Zhuang A, Forbes JM.

Glycoconj J. 2016 Aug;33(4):645-52. doi: 10.1007/s10719-016-9693-z. Epub 2016 Jun 6. Review.

PMID:
27270766
17.

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.

Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, Koepsell H, Vallon V, Pollock C, Panchapakesan U, Forbes JM.

Sci Rep. 2016 May 26;6:26428. doi: 10.1038/srep26428. Erratum in: Sci Rep. 2016 Jul 07;6:28124.

18.

Mitochondria-Power Players in Kidney Function?

Forbes JM.

Trends Endocrinol Metab. 2016 Jul;27(7):441-442. doi: 10.1016/j.tem.2016.05.002. Epub 2016 May 20. Review.

PMID:
27215468
19.

Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial.

de Courten B, de Courten MP, Soldatos G, Dougherty SL, Straznicky N, Schlaich M, Sourris KC, Chand V, Scheijen JL, Kingwell BA, Cooper ME, Schalkwijk CG, Walker KZ, Forbes JM.

Am J Clin Nutr. 2016 Jun;103(6):1426-33. doi: 10.3945/ajcn.115.125427. Epub 2016 Mar 30.

PMID:
27030534
20.

Antigen-encoding bone marrow terminates islet-directed memory CD8+ T-cell responses to alleviate islet transplant rejection.

Coleman MA, Jessup CF, Bridge JA, Overgaard NH, Penko D, Walters S, Borg DJ, Galea R, Forbes JM, Thomas R, Coates PT, Grey ST, Wells JW, Steptoe RJ.

Diabetes. 2016 May;65(5):1328-1340. doi: 10.2337/db15-1418. Epub 2016 Mar 9.

21.

Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes.

Coughlan MT, Nguyen TV, Penfold SA, Higgins GC, Thallas-Bonke V, Tan SM, Van Bergen NJ, Sourris KC, Harcourt BE, Thorburn DR, Trounce IA, Cooper ME, Forbes JM.

Clin Sci (Lond). 2016 May;130(9):711-20. doi: 10.1042/CS20150838. Epub 2016 Feb 1.

PMID:
26831938
22.

Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis.

Coughlan MT, Higgins GC, Nguyen TV, Penfold SA, Thallas-Bonke V, Tan SM, Ramm G, Van Bergen NJ, Henstridge DC, Sourris KC, Harcourt BE, Trounce IA, Robb PM, Laskowski A, McGee SL, Genders AJ, Walder K, Drew BG, Gregorevic P, Qian H, Thomas MC, Jerums G, Macisaac RJ, Skene A, Power DA, Ekinci EI, Wijeyeratne XW, Gallo LA, Herman-Edelstein M, Ryan MT, Cooper ME, Thorburn DR, Forbes JM.

Diabetes. 2016 Apr;65(4):1085-98. doi: 10.2337/db15-0864. Epub 2016 Jan 28.

23.

Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.

Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM, Szeto CC, McWhinney BC, Ungerer JP, Campbell KL.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):223-31. doi: 10.2215/CJN.05240515. Epub 2016 Jan 15.

24.

Tapping into Mitochondria to Find Novel Targets for Diabetes Complications.

Flemming NB, Gallo LA, Ward MS, Forbes JM.

Curr Drug Targets. 2016;17(12):1341-9. Review.

PMID:
26212267
25.

Impairment of Liver Glycogen Storage in the db/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics?

Sullivan MA, Harcourt BE, Xu P, Forbes JM, Gilbert RG.

Curr Drug Targets. 2015;16(10):1088-93. Review.

PMID:
26212261
26.

Palatability assessment of an oral recuperation fluid in healthy dogs during the perioperative period.

Forbes JM, Bell A, Twedt DC, Martin LE, Lappin MR, Mathis JC, Sullivan LA.

Top Companion Anim Med. 2015 Mar;30(1):35-8. doi: 10.1053/j.tcam.2015.01.002. Epub 2015 Jan 17.

PMID:
26041597
27.

Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes.

Salonen KM, Ryhänen SJ, Forbes JM, Borg DJ, Härkönen T, Ilonen J, Simell O, Veijola R, Groop PH, Knip M.

Diabetes Care. 2015 Apr;38(4):665-70. doi: 10.2337/dc14-1186. Epub 2015 Jan 8.

PMID:
25573878
28.

A rapid extraction method for glycogen from formalin-fixed liver.

Sullivan MA, Li S, Aroney ST, Deng B, Li C, Roura E, Schulz BL, Harcourt BE, Forbes JM, Gilbert RG.

Carbohydr Polym. 2015 Mar 15;118:9-15. doi: 10.1016/j.carbpol.2014.11.005. Epub 2014 Nov 15.

PMID:
25542100
29.

Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy.

Thallas-Bonke V, Jha JC, Gray SP, Barit D, Haller H, Schmidt HH, Coughlan MT, Cooper ME, Forbes JM, Jandeleit-Dahm KA.

Physiol Rep. 2014 Nov 3;2(11). pii: e12192. doi: 10.14814/phy2.12192. Print 2014 Nov 1.

30.

Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress.

Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, Das I, Wang R, Chen AC, Loudovaris T, Kay TW, Thomas HE, Whitehead JP, Forbes JM, Prins JB, McGuckin MA.

Nat Med. 2014 Dec;20(12):1417-26. doi: 10.1038/nm.3705. Epub 2014 Nov 2.

PMID:
25362253
31.

Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy.

Fukami K, Yamagishi S, Coughlan MT, Harcourt BE, Kantharidis P, Thallas-Bonke V, Okuda S, Cooper ME, Forbes JM.

Diabetol Metab Syndr. 2014 Aug 13;6(1):86. doi: 10.1186/1758-5996-6-86. eCollection 2014.

32.

Type 2 diabetes, skin autofluorescence, and brain atrophy.

Moran C, Münch G, Forbes JM, Beare R, Blizzard L, Venn AJ, Phan TG, Chen J, Srikanth V.

Diabetes. 2015 Jan;64(1):279-83. doi: 10.2337/db14-0506. Epub 2014 Jul 22.

33.

SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial.

Rossi M, Johnson DW, Morrison M, Pascoe E, Coombes JS, Forbes JM, McWhinney BC, Ungerer JP, Dimeski G, Campbell KL.

BMC Nephrol. 2014 Jul 4;15:106. doi: 10.1186/1471-2369-15-106.

34.

Stress in the kidney is the road to pERdition: is endoplasmic reticulum stress a pathogenic mediator of diabetic nephropathy?

Zhuang A, Forbes JM.

J Endocrinol. 2014 Sep;222(3):R97-111. doi: 10.1530/JOE-13-0517. Epub 2014 Jun 30. Review.

PMID:
24982467
35.

Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes.

Tesch G, Sourris KC, Summers SA, McCarthy D, Ward MS, Borg DJ, Gallo LA, Fotheringham AK, Pettit AR, Yap FY, Harcourt BE, Tan AL, Kausman JY, Nikolic-Paterson D, Kitching AR, Forbes JM.

Diabetologia. 2014 Sep;57(9):1977-85. doi: 10.1007/s00125-014-3291-z. Epub 2014 Jun 24.

PMID:
24957662
36.

Circulating concentrations of soluble receptor for AGE are associated with age and AGER gene polymorphisms in children with newly diagnosed type 1 diabetes.

Salonen KM, Ryhänen SJ, Forbes JM, Härkönen T, Ilonen J, Laine AP, Groop PH, Knip M; Finnish Pediatric Diabetes Register.

Diabetes Care. 2014 Jul;37(7):1975-81. doi: 10.2337/dc13-3049. Epub 2014 Apr 17.

PMID:
24742661
37.

Dietary glycotoxins exacerbate progression of experimental fatty liver disease.

Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, Forbes JM, Angus PW.

J Hepatol. 2014 Apr;60(4):832-8. doi: 10.1016/j.jhep.2013.11.033. Epub 2013 Dec 6.

PMID:
24316518
38.

Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease.

Ward MS, Fortheringham AK, Cooper ME, Forbes JM.

Curr Opin Pharmacol. 2013 Aug;13(4):654-61. doi: 10.1016/j.coph.2013.06.009. Epub 2013 Jul 16. Review.

PMID:
23871446
39.

Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects.

Forbes JM, Sourris KC, de Courten MP, Dougherty SL, Chand V, Lyons JG, Bertovic D, Coughlan MT, Schlaich MP, Soldatos G, Cooper ME, Straznicky NE, Kingwell BA, de Courten B.

Amino Acids. 2014 Feb;46(2):321-6. doi: 10.1007/s00726-013-1542-9. Epub 2013 Jul 6.

PMID:
23832534
40.

Report on ISN Forefronts, Melbourne, Australia, 4-7 October 2012: tubulointerstitial disease in diabetic nephropathy.

Forbes JM, Harris DC, Cooper ME.

Kidney Int. 2013 Oct;84(4):653-6. doi: 10.1038/ki.2013.89. Epub 2013 May 22.

41.

Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion.

Siebel AL, Natoli AK, Yap FY, Carey AL, Reddy-Luthmoodoo M, Sviridov D, Weber CI, Meneses-Lorente G, Maugeais C, Forbes JM, Kingwell BA.

Circ Res. 2013 Jul 5;113(2):167-75. doi: 10.1161/CIRCRESAHA.113.300689. Epub 2013 May 15.

PMID:
23676183
42.

Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressure.

Sourris KC, Lyons JG, Dougherty SL, Chand V, Straznicky NE, Schlaich MP, Grima MT, Cooper ME, Kingwell BA, de Courten MP, Forbes JM, de Courten B.

Clin Chem Lab Med. 2014 Jan 1;52(1):129-38. doi: 10.1515/cclm-2012-0850.

PMID:
23525877
43.

Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease.

Forbes JM, Ke BX, Nguyen TV, Henstridge DC, Penfold SA, Laskowski A, Sourris KC, Groschner LN, Cooper ME, Thorburn DR, Coughlan MT.

Antioxid Redox Signal. 2013 Aug 1;19(4):331-43. doi: 10.1089/ars.2012.4719. Epub 2013 Mar 1.

PMID:
23320803
44.

Glucose homeostasis can be differentially modulated by varying individual components of a western diet.

Forbes JM, Cowan SP, Andrikopoulos S, Morley AL, Ward LC, Walker KZ, Cooper ME, Coughlan MT.

J Nutr Biochem. 2013 Jul;24(7):1251-7. doi: 10.1016/j.jnutbio.2012.09.009. Epub 2013 Jan 11.

PMID:
23313044
45.

Mechanisms of diabetic complications.

Forbes JM, Cooper ME.

Physiol Rev. 2013 Jan;93(1):137-88. doi: 10.1152/physrev.00045.2011. Review.

46.

Coming full circle in diabetes mellitus: from complications to initiation.

Harcourt BE, Penfold SA, Forbes JM.

Nat Rev Endocrinol. 2013 Feb;9(2):113-23. doi: 10.1038/nrendo.2012.236. Epub 2013 Jan 8. Review.

PMID:
23296171
47.

A legal review of autism, a syndrome rapidly gaining wide attention within our society.

Cohen JA, Dickerson TA, Forbes JM.

Albany Law Rev. 2013-2014;77(2):389-423. No abstract available.

PMID:
24851321
48.

Insulin infusion reduces hepatocyte growth factor in lean humans.

de Courten B, de Courten MP, Dougherty S, Forbes JM, Potts JR, Considine RV.

Metabolism. 2013 May;62(5):647-50. doi: 10.1016/j.metabol.2012.10.013. Epub 2012 Nov 26.

PMID:
23190875
49.

Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content.

Thallas-Bonke V, Coughlan MT, Tan AL, Harcourt BE, Morgan PE, Davies MJ, Bach LA, Cooper ME, Forbes JM.

Nephrology (Carlton). 2013 Jan;18(1):47-56. doi: 10.1111/j.1440-1797.2012.01665.x.

PMID:
23046363
50.

Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.

Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM, McMullen JR, Ritchie RH.

Diabetologia. 2012 May;55(5):1544-53. doi: 10.1007/s00125-012-2495-3. Epub 2012 Feb 29.

PMID:
22374176

Supplemental Content

Loading ...
Support Center